Citations

Showing 10 of 108152 citations.

Reply to: Burosumab for Tumor-Induced Osteomalacia: not Enough of a Good Thing
Miller, Paul D. , Peacock, Munro , Rauch, Frank , Luca, Diana, Cimms, Tricia, Roberts, Mary Scott , Beur, Suzanne M. Jan de , Weber, Thomas J. , Insogna, Karl , Kumar, Rajiv , Martín, Javier San , Carpenter, Thomas O

Mayo Clinic

Journal of Bone and Mineral Research | May 24, 2021 | Volume: 36 | Issue: 12 | Pages: 2455-2456

10.1002/jbmr.4317 | PMID 34030212 Get It

The Dynamics of SARS-CoV-2 (RT-PCR) Testing
Joyce, Nicole , Seim, Lynsey A. , Smerina, Michael , Seim, Lynsey

Mayo Clinic

Case Reports in Medicine | May 24, 2021 | Volume: 2021 | Issue: No issue available | Pages: 1-7

10.1155/2021/6688303 | PMID 34054967 Get It

The COVID-19 pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is estimated to have affected 6.2 million people in the United States and 27.5 million people worldwide as of September 9, 2020. On February 2, 2020, the Secretary of the Department of Health and Human Services (HHS) determined that the public health emergency justified the development and emergency use of “in vitro diagnostics for the detection and/or diagnosis of the virus that causes COVID-19” by activating the Emergency Use Authorization (EUA) authority under section 564 of the Federal Food, Drug, and Cosmetic Act. Unfortunately, effective mitigation efforts were thwarted early in the outbreak resulting in an expansion of the initial EUA on February 29, 2020, to improve accessibility to in vitro diagnostic testing. Expectantly, the development and deployment of SARS-CoV-2 testing including RT-PCR expanded rapidly in the weeks following the EUA expansion. These newly developed and approved SARS-CoV-2 RT-PCR tests boast impressive positive and negative agreement rates nearing 100%. Despite the exceptionally high rates of agreement, caution is advised as the RT-PCR tests approved under the COVID-19 EUA are in vitro analyses developed with samples artificially doped with SARS-CoV-2 RNA. These tests therefore do not have clinically applicable sensitivity and specificity because they lack a “gold standard” for diagnosis. Here we present three challenging cases requiring cautious interpretation of the newest generation of RT-PCR molecular detection assays, highlighting the major challenges faced by providers treating patients potentially infected with SARS-CoV-2.
Genome-Wide Interaction Analysis of Menopausal Hormone Therapy Use and Breast Cancer Risk Among 62,370 Women
Wang, Xiaoliang , Auer, Paul L. , Wang, Qin , Bolla, Manjeet K. , Aronson, Kristan J. , Lee, Derrick G. , Mulot, Claire , Patel, Alpa V. , Hoppe, Reiner , Lo, Wing‐Yee, Brüning, Thomas , Hamann, Ute , Larson, Nicole L. , Ruddy, Kathryn J. , Haiman, Christopher A. , Krüger, Ute , Wagner, Philippe , Vachon, Celine M. , Hunter, David J. , Andrulis, Irene L., Linet, Martha S. , Prentice, Ross L. , Easton, Douglas F. , Chang‐Claude, Jenny , Lindström, Sara , Wang, Xiaoliang , Middha, Pooja , Dennis, Joe , Dunning, Alison M. , Lush, Michael J. , Michailidou, Kyriaki , Murphy, Rachel A. , Brooks‐Wilson, Angela , Cordina‐Duverger, Emilie , Guénel, Pascal , Truong, Thérèse , Teras, Lauren R. , Dossus, Laure , Kaaks, Rudolf , Czene, Kamila , Gabrielson, Marike , Hall, Per N , Eriksson, Mikael , Jung, Audrey , Becher, Heiko , Couch, Fergus J. , Olson, Janet E. , Giles, Graham G. , MacInnis, Robert J. , Southey, Melissa C. , Marchand, Loı̈c Le , Wilkens, Lynne R. , Olsson, Håkan , Augustinsson, Annelie , Scott, Christopher G. , Winham, Stacey J. , Vachon, Celine M. , Perou, Charles M. , Olshan, Andrew F. , Troester, Melissa A. , Eliassen, A. Heather , Tamimi, Rulla M. , Brantley, Kristen D. , Figueroa, Jonine D. , Chanock, Stephen Jacob , Ahearn, Thomas U. , García‐Closas, Montserrat , Evans, D. Gareth , Newman, William G. , Veen, Elke M. van , Howell, Anthony , Wolk, Alicja , Håkansson, Niclas , Anton‐Culver, Hoda , Ziogas, Argyrios , Jones, Michael E. , Orr, Nick , Schoemaker, Minouk J. , Swerdlow, Anthony J. , Kitahara, Cari M. , Milne, Roger L. , Kraft, Peter

Mayo Clinic

No container title available | May 24, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-532921/v1 Get It

Abstract Background: Use of menopausal hormone therapy (MHT) is associated with increased risk for breast cancer. However, the relevant mechanisms and its interaction with genetic variants are not fully understood. Methods: We conducted a genome-wide interaction analysis between MHT use and genetic variants for breast cancer risk in 27,585 cases and 34,785 controls from 26 observational studies. All women were post-menopausal and of European ancestry. Multivariable logistic regression models were used to test for multiplicative interactions between genetic variants and current MHT use. We considered interaction p-values<5x10-8 as genome-wide significant, and p-values<1x10-5 as suggestive. Linkage disequilibrium (LD)-based clumping was performed to identify independent candidate variants.Results: None of the 9.7 million genetic variants tested for interactions with MHT use reached genome-wide significance. Only 213 variants, representing 18 independent loci, had p-values<1x105. The strongest evidence was found for rs4674019 (p-value=2.27x10-7), which showed genome-wide significant interaction (p-value=3.8x10-8) with current MHT use when analysis was restricted to population-based studies only. Limiting the analyses to combined estrogen-progesterone MHT use only or to estrogen receptor (ER) positive cases did not identify any genome-wide significant evidence of interactions. Conclusions: In this large genome-wide SNP-MHT interaction study of breast cancer, we found no strong support for common genetic variants modifying the effect of MHT on breast cancer risk. These results suggest that common genetic variation has limited impact on the observed MHT–breast cancer risk association.
Evaluation and Management of Autonomic Dysreflexia and Other Autonomic Dysfunctions: Preventing the Highs and Lows
Linsenmeyer, Todd A. , Beck, Lisa A., Elliott, Stacy , Gorman, Peter H. , Vogel, Lawrence C. , Wecht, Jill M. , Clay, Sarah, Krassioukov, Andrei V. , Kirshblum, Steven

Mayo Clinic

Topics in Spinal Cord Injury Rehabilitation | May 24, 2021 | Volume: 27 | Issue: 2 | Pages: 225-290

10.46292/sci2702-225 | PMID 34108837 Get It

No Significant Difference in Post-ERCP Bleeding Rates Between Dual Antiplatelet Agents and Aspirin Alone
Goel, Akshay , Bansal, Vikas , Brahmbhatt, Bhaumik , Sarkar, Avik , Bansal, Vikas , Bhurwal, Abhishek , Mutneja, Hemant , Patel, Anish V.

Mayo Clinic

Journal of Clinical Gastroenterology | May 24, 2021 | Volume: 56 | Issue: 6 | Pages: 546-551

10.1097/mcg.0000000000001559 | PMID 34028396 Get It

Background: Several professional society guidelines suggest holding antiplatelet agents before high-risk procedures. However, there is lack of high-grade evidence to support the recommendation as most of the studies have been single center with small sample sizes. We aimed to perform the first systematic review and meta-analysis comparing dual antiplatelet therapy (DAPT) versus aspirin alone in terms of postendoscopic retrograde cholangiopancreatography (ERCP) bleeding. Methods Three independent reviewers performed a comprehensive review of all original articles published from inception to May 2020, evaluating the post-ERCP bleeding rate in setting of DAPT. Primary outcomes were the overall post-ERCP bleeding rate with the use of dual antiplatelet therapy; comparison of post-ERCP bleeding rate in patients with DAPT versus aspirin alone. Secondary outcomes were comparison of immediate and delayed post-ERCP bleeding outcomes in the 2 cohorts. Results: Six studies were included after a thorough search was concluded using the key words. The pooled analysis of studies revealed an overall post-ERCP bleeding rate of 5.7% (95% confidence interval: 3-10.6) on sustained DAPT. Post-ERCP bleeding in DAPT Cohort was not significantly higher as compared with aspirin only Cohort (odds ratio: 1.14, 95% confidence interval: 0.46-2.81). The immediate bleeding and delayed bleeding rates cannot be generalized due to low number of studies. Conclusions: The first systematic review and meta-analysis showed that post-ERCP bleeding rates are not significantly higher in DAPT cohort as compared with aspirin alone. Therefore, the risk of bleeding is less likely related to the antiplatelet agents and more likely related to the procedure itself.
An Open-label, Multicenter Study to Assess the Efficacy and Safety of a Novel Probiotic Blend in Patients With Functional Gastrointestinal Symptoms
Harris, Lucinda A. , Moftah, Karim, Franklin, Howard, Cash, Brooks D.

Mayo Clinic

Journal of Clinical Gastroenterology | May 24, 2021 | Volume: 56 | Issue: 5 | Pages: 444-451

10.1097/mcg.0000000000001567 | PMID 34028393 Get It

Goal: A novel 5-strain (Bl-04, Bi-07, HN019, NCFM, and Lpc-37) probiotic blend was developed and its safety and efficacy were evaluated in patients with functional gastrointestinal (GI) symptoms. Background: These strains administered together have not previously been investigated. Study: Patients aged 18 to 75 years with functional GI symptoms were eligible for inclusion in a single-arm, open-label, multicenter study (NCT04155801). An oral capsule containing the novel probiotic blend was administered once daily for 30 days. The primary efficacy endpoint was patient-reported improvement in overall GI well-being at day 30. Secondary efficacy endpoints included changes in GI symptoms assessed using the GI Health Symptom Questionnaire. Incidence of treatment-emergent adverse events was recorded at all visits. Results: Of 188 enrolled patients, 72.3% were female and mean (SD) age was 44.1 (13.4) years. At day 30, 85.1% of patients achieved the primary endpoint, a positive response signifying improvement in overall GI well-being. Improvements from baseline were reported at day 30 in diarrhea frequency (baseline frequency≥3 to 4 d/wk) and severity (baseline severity≥5/10) for 75.8% and 87.3% of patients, respectively. Over the same time period, constipation frequency (baseline frequency≥3 to 4 d/wk) and severity (baseline severity≥5/10) improved in 73.6% and 80.4% of patients, respectively. Most patients reported improvements at day 30 in frequency and severity of straining, urgency, abdominal pain/discomfort, bloating, and distention. Improvements reported at day 30 were generally observable at day 14. No safety signals were identified. Conclusion: A novel 5-strain probiotic blend improved functional GI symptoms and was safe.
Discontinuing Antiseizure Medication in Neonates With Acute Symptomatic Seizures—Primum non nocere
Payne, Eric T. , Wirrell, Elaine

Mayo Clinic

JAMA Neurology | May 24, 2021 | Volume: 78 | Issue: 7 | Pages: 797

10.1001/jamaneurol.2021.1218 | PMID 34028499 Get It

Clinical features and survival outcomes in patients with chronic myelomonocytic leukemia arising in the context of germline predisposition syndromes
Martin, Emma C. St. , Wudhikarn, Kitsada , Mangaonkar, Abhishek A. , Tefferi, Ayalew , Gangat, Naseema , Altman, Jessica K. , Godley, Lucy A. , Patnaik, Mrinal M. , St Martin, Emma C , Mangaonkar, Abhishek A. , Hogan, William, Tefferi, Ayalew , Patnaik, Mrinal , Godley, Lucy A , Ferrer, Alejandro , Hogan, William J. , Lasho, Terra L.

Mayo Clinic

American Journal of Hematology | May 24, 2021 | Volume: 96 | Issue: 9 | Pages: No page available

10.1002/ajh.26250 | PMID 34028844 Get It

Neurodegeneration of the visual word form area in a patient with word form alexia
Chandregowda, Adithya , Lowe, Val J. , Whitwell, Jennifer L. , Josephs, Keith A. , Duffy, Joseph R. , Machulda, Mary M.

Mayo Clinic

Neurology and Clinical Neuroscience | May 24, 2021 | Volume: 9 | Issue: 4 | Pages: 359-360

10.1111/ncn3.12516 | PMID 34373787 Get It

Classification of Monocytes, Promonocytes and Monoblasts Using Deep Neural Network Models: An Area of Unmet Need in Diagnostic Hematopathology
Osman, Mazen, Akkus, Zeynettin , Nguyen, Phuong L., Roh, Dana J., Al‐Kali, Aref , Patnaik, Mrinal M. , Nanaa, Ahmad , Rizk, Samia , Salama, Mohamed E. , Roh, Dana, Nanaa, Ahmad , Akkus, Zeynettin , Jevremović, Dragan

Mayo Clinic

Journal of Clinical Medicine | May 24, 2021 | Volume: 10 | Issue: 11 | Pages: 2264

10.3390/jcm10112264 | PMID 34073699 Get It

The accurate diagnosis of chronic myelomonocytic leukemia (CMML) and acute myeloid leukemia (AML) subtypes with monocytic differentiation relies on the proper identification and quantitation of blast cells and blast-equivalent cells, including promonocytes. This distinction can be quite challenging given the cytomorphologic and immunophenotypic similarities among the monocytic cell precursors. The aim of this study was to assess the performance of convolutional neural networks (CNN) in separating monocytes from their precursors (i.e., promonocytes and monoblasts). We collected digital images of 935 monocytic cells that were blindly reviewed by five experienced morphologists and assigned into three subtypes: monocyte, promonocyte, and blast. The consensus between reviewers was considered as a ground truth reference label for each cell. In order to assess the performance of CNN models, we divided our data into training (70%), validation (10%), and test (20%) datasets, as well as applied fivefold cross validation. The CNN models did not perform well for predicting three monocytic subtypes, but their performance was significantly improved for two subtypes (monocyte vs. promonocytes + blasts). Our findings (1) support the concept that morphologic distinction between monocytic cells of various differentiation level is difficult; (2) suggest that combining blasts and promonocytes into a single category is desirable for improved accuracy; and (3) show that CNN models can reach accuracy comparable to human reviewers (0.78 ± 0.10 vs. 0.86 ± 0.05). As far as we know, this is the first study to separate monocytes from their precursors using CNN.